Montréal-based Valeant Pharmaceuticals International Inc. (NYSE: VRX and TSX: VRX) has completed its acquisition of eye care specialist Bausch + Lomb Holdings Inc. from U.S. private equity firm Warburg Pincus, which acquired the Rochester, New York-based company in 2007. Valeant in May agreed to pay US$8.7 billion in cash, of which around US$4.5 billion would go to Warburg Pincus and other investors, and around US$4.2 billion would be used to repay Bausch + Lomb’s debt.
Valeant Pharmaceuticals International, Inc. Completes Acquisition Of Bausch + Lomb
LAVAL, Quebec, Aug. 6, 2013 /CNW/ – Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced it has completed the previously announced acquisition of Bausch + Lomb Holdings Incorporated. Bausch + Lomb is a leading global eye health company that has a broad portfolio of eye health products, including well-known prescription and OTC brands Besivance, Lotemax, Ocuvite and PreserVision; vision care brands Biotrue ONEday, PureVision, renu and Boston; and surgical brands enVista, Storz, Stellaris and VICTUS.
About Valeant Pharmaceuticals International, Inc.
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology and branded generics. More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.
Laurie W. Little
SOURCE Valeant Pharmaceuticals International, Inc.
Photo courtesy of Shutterstock.